iTeos Therapeutics Inc has appointed two experienced executives to its board of directors as it advances clinical-stage products for cancer. Tony Ho is head of R&D at Crispr Therapeutics AG, the gene editing company, while Robert Iannone is chief medical officer and head of R&D at Jazz Pharmaceuticals Plc. Both executives have also held senior positions in oncology at AstraZeneca Plc. Dr Ho led the development and commercialisation of the cancer drugs Lynparza and Imfinzi, while Dr Iannone was the UK company’s head of immuno-oncology.
Dr Ho earned his medical degree at the Johns Hopkins University School of Medicine and has a BS in electrical engineering from the University of California, Los Angeles. Dr Iannone has an MD degree from Yale University and a BS degree from The Catholic University of America.
iTeos is headquartered in Cambridge, US with a research centre in Belgium.
The company announced the appointments on 3 May 2021.
Copyright 2021 Evernow Publishing Ltd